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Abstract
Loss of genome-wide methylation is a common feature of cancer, and the degree of hypomethylation has been correlated
with genomic instability. Global methylation of repetitive elements possibly arose as a defense mechanism against parasitic
DNA elements, including retrotransposons and viral pathogens. Given the alterations of global methylation in both viral
infection and cancer, we examined genome-wide methylation levels in head and neck squamous cell carcinoma (HNSCC), a
cancer causally associated with human papilloma virus (HPV). We assayed global hypomethylation levels in 26 HNSCC
samples, compared with their matched normal adjacent tissue, using Pyrosequencing-based methylation assays for LINE
repeats. In addition, we examined cell lines derived from a variety of solid tumors for LINE and SINE (Alu) repeats. The degree
of LINE and Alu hypomethylation varied among different cancer cell lines. There was only moderate correlation between
LINE and Alu methylation levels, with the range of variation in methylation levels being greater for the LINE elements. LINE
hypomethylation was more pronounced in HPV-negative than in HPV-positive tumors. Moreover, genomic instability, as
measured by genome-wide loss-of-heterozygosity (LOH) single nucleotide polymorphism (SNP) analysis, was greater in
HNSCC samples with more pronounced LINE hypomethylation. Global hypomethylation was variable in HNSCC. Its
correlation with both HPV status and degree of LOH as a surrogate for genomic instability may reflect alternative oncogenic
pathways in HPV-positive versus HPV-negative tumors.
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Introduction
DNA methylation is an epigenetic DNA modification that
occurs via the action of DNA methyltransferases on CpG
dinucleotides. Methylated regions of DNA are associated with
chromatin remodeling, generally occurring in areas of more
condensed chromatin and decreased transcriptional activity [1,2].
Renewed interest in this process arose after it was recognized that
two types of aberrant methylation patterns are present in cancer
cells [1,3]. The first is gene-specific hyper-methylation, where
CpG islands in the promoter regions of genes acquire increased
methylation, generally leading to reduced expression of the
downstream gene. The second is genome-wide hypo-methylation,
a large percentage of which occurs in repetitive DNA elements. In
malignancy, global methylation is often aberrantly reduced,
whereas gene-specific methylation is often aberrantly increased.
While the effects of gene-specific hypermethylation (e.g., reduced
expression of a gene that is important for growth control) are easily
appreciated, the effects of reduced global methylation are more
vague [1,3].
It has been hypothesized that DNA methylation initially evolved
as a defense mechanism against viral and other DNA pathogens as a
way to silence foreign DNA sequences [4–6]. This is consistent with
theobservationthatLINEandSINE(Alu)elements,originatingfrom
transposable elements, are heavily methylated in normal cells.
Methylation of the HPV viral genome upon integration into the host
genome has been reported, and changes in methylation of HPV
DNA have been associated with tumorigenesis [7,8].
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by associations between clinical outcome and global methylation
levels in a number of cancer types [9–11]. From a mechanistic
standpoint, global methylation appears to be related to cancer
progression, since loss of global methylation tends to become more
pronounced as precancerous lesions progress [12,13]. Further-
more, in colon cancer cells, loss of LINE methylation is inversely
correlated with microsatellite instability and is directly correlated
with chromosome instability [14,15].
We hypothesized that global methylation levels in cancer,
represented by levels of LINE and SINE (Alu) methylation, might
be correlated with viral infection. We, therefore, examined LINE
methylation in relation to HPV status in head and neck cancers. In
contrast to cervical cancers, which are nearly all associated with
HPV infection, HNSCC is virally mediated in only a subset of
cases (25–30%) [16]. To determine the impact of viral infection on
global methylation levels in HNSCC, we developed Pyrosequen-
cing-based methylation assays for repetitive DNA elements and
compared HPV-positive with HPV-negative cancers. Previous
publications have suggested that LINE methylation is variable in
HNSCC, but did not find an association between HPV DNA
status and LINE methylation levels [17,18]. Here we show that
global hypomethylation is variable in HNSCC and correlates with
both HPV status and genomic instability.
Results
LINE/SINE (Alu) assays are precise and reproducible, but
show only moderate correlation between LINE-1 and Alu
methylation levels
To assay global methylation levels, we adapted our Pyrosequen-
cing-based Methylation Analysis (PMA) assay [19] to assess
methylation of repetitive LINE and SINE (Alu) elements, similar
to genome-wide methylation assays reported previously [20]. To
validate the assays, we performed a series of tests: (1) mixing
experiments with known amounts of methylated/unmethylated
DNA; (2) methylation studies on a variety of cancer cell lines to
compare LINE to SINE methylation and to survey global
methylation across a broad range of malignancies; and (3)
methylation of samples from different ages and genders to
eliminate these factors as possible confounders of global methyl-
ation measurements.
Stepwise increments of methylated DNA were prepared by
mixing universally unmethylated (U2M.L) DNA with universally
methylated (UM.L) DNA in various proportions. The mixed
samples were then bisulfite treated and subjected to our PMA
LINE-1 (LINE) and Alu (SINE) assays. Linear regression analysis
showed that LINE-1 and Alu methylation levels were very closely
associated with levels predicted by input fraction of methylated
DNA (r=0.995, p-value,0.0005 for LINE-1, and r=0.980, p-
value,0.0005 for Alu; Figure S1). It should be noted that even
when input DNA was completely methylated, the maximum
global methylation percentage as measured by the PMA assay is
just over 50%, not 100%. This is because individual repetitive
elements have diverged in sequence over time; and CpG
dinucleotides, if mutated to TpG dinucleotides, are indistinguish-
able from unmethylated CpGs after the bisulfite treatment. This
level of background noise is taken into account by normalizing
each result to the universally methylated control (i.e., reporting the
percent methylated reference, or PMR).
Four pools of normal DNA samples (from peripheral blood
leukocytes) were generated to assess the influence of age and
gender on LINE-1 and Alu methylation levels. Each pool (females
#40 years old, males #40 years old, females .40 years old, males
.40 years old) contained DNA from at least five individuals.
There were no sex- or age-dependent differences between the
pools in LINE-1 or Alu methylation levels (data not shown).
Each LINE-1 and Alu methylation assay was tested on a panel of
23 cancer cell lines. Different CpG sites were compared by means
of three distinct LINE-1 assays and three distinct Alu assays, each
derived from different regions of the LINE-1 and Alu consensus
sequences, respectively (Table 1). As a control, we also tested seven
normal lymphoblastoid cell lines, which showed normal levels of
methylation (all .80% in our LINE-1 assays). In contrast, as
expected from previous reports [12–14,21], many of the tumor cell
lines showed global hypomethylation, which was most pronounced
in the LINE-1 assays (Figure 1). To check the consistency between
LINE and SINE methylation levels (represented by our LINE-1
and Alu assays, respectively), we compared the degree of
correlation between results from the three LINE-1 assays, between
Table 1. LINE-1 and Alu PMA Assays.
Assays
GenBank Number







L1-1 X52235 tttattagggagtgttagatagtggg GACGGGACACCGCTGATCGTTTA tgggygtaggttagtgggtg (F) 117 6
cttcccaaataaaacaatacc
L1-2 X52235 GACGGGACACCGCTGATCGTTTA ccctcctaaccaaatacaaaat ccaaatacaaaatataatct (R) 196 4
ggtattgttttatttgggaag
L1-3 M80343 attagggagtgttagatagtggg GACGGGACACCGCTGATCGTTTA gygtaggttagtgtgtgtg (F) 123 5
ccccttacrcttcccaaat
Alu-1 [26] GACGGGACACCGCTGATCGTTTA ccaaactaaaatacaataa aaactaaaatacaataac (R) 170 3
tttttattaaaaatataaaaaattagt
Alu-2 [26] GACGGGACACCGCTGATCGTTTA tcaacctcccraataactaaaa aataactaaaattacaaac (R) 96 5
tttttattaaaaatataaaaaattagt
Alu-3 J00085 gagagaattgtttgaatttagga GACGGGACACCGCTGATCGTTTA tgaatttaggaggtgga (F) 102 4
cactatcacccaaactaaaataca
The sequence for the biotin-labeled universal primer (59–39) for the 3-primer PCR is underlined, Biotin-GGGACACCGCTGATCGTTTA. F, sequencing primer extends in the
forward direction; R, sequencing primer extends in the reverse direction. r, purine (A or G); y, pyrimidine (C or T).
doi:10.1371/journal.pone.0004941.t001
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and Alu assays. Linear regression analysis showed that the
individual LINE-1 assay results were highly correlated with each
other, for example r=0.93 for the correlation between the L1-2
and L1-3 assay results (Figure S2A). The same high degree of
correlation was present between results from the Alu assays, for
example r=0.82 for the correlation between the Alu-1 and Alu-3
assay results (Figure S2B). However, LINE-1 assay results were
only moderately correlated with Alu assay results, for example
r=0.33 comparing L1-1 and Alu-1; Figure S2C). A similar level of
moderate correlation between LINE-1 and Alu assays was reported
previously in neuroendocrine tumors [22].
LINE-1 hypomethylation of HNSCC patient samples
Matching normal, primary tumor, and where available, lymph
node metastases of head and neck patient samples (Table S1) were
tested using our PMA LINE-1 assays (Figure 2). Because of the
greater dynamic range of the LINE-1 assay and limited sample
amounts, only LINE-1 assays were performed for the remainder of
this study. In general, HNSCC primary tumors and metastatic
lymph nodes were hypomethylated compared to their matching
normal adjacent tissues. With the LINE1-1 assay, the mean primary
tumorPMR was65.5%,whilethe meannormalPMRwas90.0%(p-
value=6.7610
28 using a paired t-test). However, there was quite a
bit of variability in the primary tumors, ranging from 31.2% (severe
hypomethylation) to 90.8% (normal). The mean PMR in lymph
node metastases (73.8%; range 31.8%–93.8%) was also highly
variable, even with respect to the corresponding primary tumor,
sometimes lower and sometimes higher than the PMR of the
primary tumor with which it is associated.
HPV-positive tumors retain more LINE-1 methylation
than HPV-negative tumors
Because there was so much variability in the HNSCC tumor
PMR, we hypothesized that the level of global hypomethylation
might vary in different subgroups of HNSCC. To explore the
relationship between loss of LINE-1 hypermethylation and HPV
status, we compared the mean LINE-1 methylation level of three
Figure 1. Alu and LINE-1 methylation in a variety of tumor cell lines. A. Alu methylation using the Alu-3 assay. B. LINE-1 methylation using
the L1-3 assay. Results are reported as the PMR (percent methylated reference) normalized to the universally methylated reference DNA. Universally
unmethylated (U2M), universally methylated (UM) controls, and normal control DNA from PBLs are also shown.
doi:10.1371/journal.pone.0004941.g001
Figure 2. LINE-1 methylation in HNSCC tumor samples. Paired
tumor and normal samples and, where available, lymph node
metastases were assayed for LINE-1 methylation. PMR values are
plotted using the normal sample PMR as the x-value and primary tumor
(circles) or metastasis (triangle) PMR as the y-value. Horizontal lines
represent PMR values for universally methylation (UM) and unmethy-
lated (U2M) controls, normal lymphocytes (green) and for four HNSCC
cell lines (yellow). Box plots on the right show the mean and
distribution of primary tumors and metastases in the subset of samples
where matched metastases and primary tumors were available.
doi:10.1371/journal.pone.0004941.g002
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was HPV negative (2/2); the second group (n=8) contained
HPV DNA, yet were transcriptionally silent with respect to the E6
viral oncogene, indicating lack of expression of this oncoprotein
(+/2). The third group of tumors (n=8) was positive for HPV
DNA and E6 expression (+/+). The mean methylation level of the
three groups of tumors is statistically different, with a p-
value=0.011 for the trend (Figure 3).
We also compared global methylation levels in matched normal
adjacent tissues from the same three groups. In contrast to the
results for the primary tumors, there were no differences in global
methylation levels in the matching normal tissues and therefore no
correlation with HPV status (Figure 3). Based on a previously
reported association between LINE-1 methylation and T-N-M
stage [18], we looked for such an association in our sample set, but
found none (p-value=0.31).
Levels of LINE-1 hypomethylation and LOH in HNSCC
tumors are correlated
Colon cancer cell lines with more pronounced LINE
hypomethylation were previously reported to have a higher
degree of LOH [14,15]. To examine whether this correlation
held true in our HNSCC patient samples, we performed a global
LOH analysis using 10K SNPChip data. Genotypes were
compared between normal adjacent tissue and matched tumor
samples; informative loci were those that were heterozygous in
the normal tissue. Figure 4 shows a plot of the percentage of
informative loci for each primary tumor with LOH versus the
degree of LINE-1 methylation in the same specimen. We fit a
linear trend to the data, which showed a Pearson correlation of
20.494, with a p-value=0.017. As a check of robustness, we also
calculated the Spearman (rank-based) correlation, which was
also significant. The Spearman correlation coefficient for this
relationship was 20.428 (p-value=0.042), establishing that LOH
was indeed significantly correlated with the degree of LINE
hypomethylation.
Discussion
We developed several LINE (LINE-1) and SINE (Alu)
methylation assays with PCR primers in conserved regions of
these repetitive elements. These assays utilize multiple CpG sites
(3–6) to determine methylation levels and enable the simultaneous
amplification of many individual LINE and SINE elements
throughout the human genome as representative genomic
landmarks for global methylation analysis. As expected, results
from individual LINE-1 assays were very well correlated with
results from other LINE-1 assays, despite measuring methylation
in different regions of the LINE-1 sequence. The same is true for
Alu assays, with high correlation between results from three
different assays. However, when LINE-1 and Alu methylation
levels were compared with each other, the correlation was more
modest, only about 40%. The reasons for this lower correlation
may be related simply to differences in assay sensitivity: LINE-1
assays ranged from 0–50% methylated in mixing studies, while Alu
assays had less amplitude, ranging from 0–30% methylated,
possibly secondary to higher inter-individual background noise
due to sequence variation between individual Alu elements (Figure
S1). Another possibility is that there is a functional or biological
difference between the two types of repetitive DNA in their
methylation maintenance. LINE repeats are more frequent in
gene-poor regions of the genome, while Alu elements are more
common in gene-rich regions [23]. Since global methylation can
be measured by a variety of methods, these inter-assay differences
should be considered when comparing results using different types
of assays and studies.
Our results show decreases in global methylation in cell lines
from a variety of cancer cell types (Figure 1), similar to previously
published results for a variety of tumor types [12–14,21]. It is
worth noting that the cancer cell lines in general had lower levels
of methylation than the HNSCC samples, perhaps reflecting a
longer time to accumulate methylation loss or the clonal nature of
these cell lines. However, some cell lines (e.g., RKO) had little if
Figure 3. LINE-1 methylation levels are lower in HPV-negative
HNSCC. Box plots of methylation levels (PMR) of HNSCC primary
tumors (right in each pair) and normal adjacent tissue (left in each pair)
are shown according to HPV status. +/+, HPV-positive and expressing E6
viral mRNA; +/2, HPV-positive but transcriptionally silent; and 2/2,
HPV negative.
doi:10.1371/journal.pone.0004941.g003
Figure 4. LINE-1 hypomethylation is correlated with degree of
LOH in HNSCC. LINE-1 methylation is plotted as PMR, and LOH is the
fraction of 10K SNP loci that show LOH relative to all informative loci.
Pearson correlation coefficient is 20.494 (p-value=0.01) for the
correlation between the two values.
doi:10.1371/journal.pone.0004941.g004
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tumors, that there is variability in the underlying biology. Further
research into what causes this variability could provide important
information about pathways of and the role of epigenetic
alterations in cancer progression.
Our results demonstrate a positive correlation between
maintenance of normal LINE methylation and HPV-positivity.
In addition, maintenance of normal LINE methylation was also
correlated with less LOH or genome instability. If LOH is viewed
as a surrogate for chromosome instability (CIN), this result is
consistent with the previously reported result that colon cancers
also have an association between CIN and loss of LINE
hypermethylation [14,15]. Thus, it is tempting to speculate that
LINE methylation and CIN are causally related, perhaps via
methylation’s known association with more densely chromatin
packaging, which may translate into more fidelity during
chromosome segregation and therefore less LOH. However, our
results and previously reported results are purely correlative;
functional studies will be necessary before this causal relationship
can be established.
The novel finding in our results is that HPV-positivity is
correlated with maintenance of LINE methylation. A recent
epidemiologic study identifying risk factors for LINE-1 hypo-
methylation reported no significant association between HPV
DNA status and LINE-1 methylation levels [17]. However, there
were methodological differences between that and our study,
including the use of both HPV E6 DNA and RNA status in the
assignment of HPV status, the use of a different methylation assay,
and the use of methylation level as a continuous variable in the
analysis. Although Furniss and colleagues did not show a direct
association, they showed that outcomes varied by LINE-1
methylation levels for HPV-negative tumors [23]. Further studies
are needed to clarify the association between HPV status and
LINE methylation. One possible hypothesis is that in an attempt
to silence the HPV virus, infected cells induce a more exuberant
methylation response, harkening back to the origins of methylation
as a viral defense mechanism. Although this will again require
mechanistic studies or perhaps studies in additional types of virally
mediated cancers (e.g., Hepatitis B and C mediated HCC
compared with non-virally induced HCC, or EBV+ lymphoma
vs. EBV- lymphoma) to establish causality, our results along with
those of Furniss and colleagues [17] certainly provide more
support for the hypothesis that HPV-positive HNSCC and HPV-
negative HNSCC represent distinct biologic entities that arise via
separate oncogenic pathways.
In summary, we developed several new LINE (LINE-1) and
SINE (Alu) whole-genome methylation assays, which we applied to
determine the methylation status of a variety of cancer cell lines
and HNSCC primary tumor samples. We find that cancer cell
lines in general have decreased methylation levels of repetitive
elements. Even more variability in LINE-1 methylation was noted
within HNSCC samples. Importantly, we discovered a correlation
between HPV-negativity, increased genome instability, and loss of
genome methylation. This correlation reinforces the concept that
HPV-positive and HPV-negative cancers are biologically distinct
and provides a basis for future studies to further define the biologic
mechanism underlying these findings.
Materials and Methods
Patient samples and cell lines
Matched tumor/normal adjacent tissue samples, and when
available cervical lymph node metastases from HNSCC patients
were collected at Ohio State University as described previously
(Table S1) [24]. Genomic DNA was extracted from the DNA-
protein phase of TriZol-extracted tissues according to the
manufacturer’s suggestions (Invitrogen). DNA was extracted using
the PureGene kit (Gentra) on cell pellets from four HNSCC cell
lines (SCC-4, SCC-9, SCC-15 and SCC-25), five lung cancer cell
lines (H1395, H520, H2170, SK-MES-1 and SW-900), one breast
cancer cell line (MCF7), one cervical cancer cell line (HeLa), three
brain cancer cell lines (U251, SK-N-AS and M059K), one uterine
cancer cell line (AN3CA), one sarcoma cell line (HT1080), one
kidney cancer cell line (HEK293), and six colon cancer cell lines
(LoVo, SW48, HCT-15, DLD-1, COLO 320DM and RKO)
according to the manufacturer’s suggestions. In addition, DNA
from the lymphoblastoid cell line BL1395 was used as a matching
control to H1395. All cell lines are available from ATCC
(Manassas, VA).
Normal pools and methylated controls
Four pools of normal samples were generated representing
different genders and ages. DNA samples were obtained from
anonymous blood donors and were a gift of Dr. Michael J.
Siciliano (University of Texas M. D. Anderson Cancer Center).
Three of the pools (females older than 40 years of age, females age
40 or under, and males age 40 or under) were each comprised of
five individuals per pool. The fourth pool (males older than 40
years of age) was comprised of six individuals. Commercially
prepared universally methylated and universally unmethylated
DNA (UM.C and U2M.C, respectively) were obtained from
Chemicon. UM.L (universally methylated DNA ) was generated as
a positive control by treating normal peripheral blood leukocyte
(PBL) DNA with the CpG methylase M.SssI (New England
Biolabs) [25]. U2M.L (universally unmethylated DNA) was
generated as a negative control by amplifying the same DNA
used to generate the positive control DNA using the GenomiPhi
kit (GE Healthcare) as described by the manufacturer.
Primers and PCR conditions
PCR primers and sequencing primers were designed by using
PSQ Assay Design software (Biotage) [26]. Three assays for SINE
(Alu) elements and three assays for LINE-1 elements were designed
(Table 1). PCR was performed in a 25 ml reaction containing
Qiagen HotStart Taq master mix (Qiagen) using 1 ml bisulfite
treated DNA (10 ng of DNA equivalents). To reduce the cost per
assay, the amplification protocol was developed using a biotiny-
lated universal primer approach. Final primer concentrations were
10 nM of the primer tailed with the universal primer, 100 nM of
the untailed primer, and 90 nM of the universal biotinylated
primer in each reaction [19]. The amplification was carried out at
the following conditions: denaturation at 95uC for 5 min, followed
by 45 cycles at 95uC for 30 sec, 45uC (SINEs) or 53uC (LINEs) for
1 min, 72uC for 45 sec, and a final extension at 72uC for 7 min
[19].
PyroMethA (PMA) and methylation assessment
Bisulfite conversion of genomic DNA was done as reported
previously [19]. Briefly, 0.5–1.0 mg of genomic DNA was treated
using the CpGenome DNA modification kit (Chemicon), including
DNA sulfonation, deamination, desalting, desulfonation and
recovery. Bisulfite-treated DNA was stored at 220uC until use.
PMA is a Pyrosequencing-based technology that can analyze CpG
methylation at multiple sites in a single assay. After a PCR
amplification using bisulfite treated DNA, Pyrosequencing was
carried out using the PSQ96HS system (Biotage) according to the
manufacturer’s protocol including single strand binding protein
(PyroGold reagents). The results were analyzed using Q-CpG
Global Methylation in HNSCC
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(
mC/(
mC+C)) for each CpG site, allowing quantitative compari-
sons. The methylation index (called MI) was calculated as the
average value of
mC/(
mC+C) for all examined CpG sites in the
assay. In general, there was very good agreement in methylation
levels among individual CpG sites in the same assay. Bisulfite-
treated UM.L was used as the universally methylated reference.
PMA data for these global methylation assays are reported as a
percentage of methylated reference (PMR) value, normalizing the
MI of each sample to the MI of the universally methylated
reference (UM.L) DNA [25].
Commercial universally methylated DNA (UM.C) and
universally unmethylated DNA (U2M.C) (Chemicon) were also
used to perform this analysis, and the result was linear
(r=0.983, p-value,0.0005 for LINE-1; Figure S1). However,
commercially available U2M was not completely unmethylated,
since a pure U2M.C sample had residual methylation of
approximately 26%, different from U2M.L prepared in our lab,
which had the expected 0% methylation. We therefore used our
own universally unmethylated DNA (U2M.L) for all further
studies.
Detection of HPV16 E6 DNA and E6 RNA to determine
HPV status
Quantitative real-time PCR was performed to detect either
HPV16 E6 DNA or E6 cDNA using the same primer/probe set
for both. The primers were designed using the HPV16 serotype,
which accounts for $90% of all HPV-positive HNSCC cases
[27]. To control for possible genomic DNA contamination in the
cDNA, amplifications of cDNA from DNAse-treated RNA that
had been prepared using the SuperScript First Strand Synthesis
System (Invitrogen) both with and without the addition of
reverse transcriptase were compared. PCR was performed in a
25 ml reaction containing iQ supermix master mix (Biorad) using
25 ng of genomic DNA or 5 ml of cDNA. Forward primer (59-
CTGCAATGTTTCAGGACCCA-39) and reverse primer (59-
TCATGTATAGTTGTTTGCAGCTCTGT-39) were added to
a final concentration of 200 nM each. The Texas Red labeled
real-time probe (59-TR-AGGAGCGACCCAGAAAGTTACCA-
CAGTT-39) was added to a final concentration of 320 nM.
Fluorescein was added to each reaction at a final concentration
of 10 pM. Each reaction was performed in triplicate. The
amplification was carried out at the following conditions:
denaturation at 95uC for 8.5 min, followed by 50 cycles at
95uC for 15 sec, 60uC for 1 min and analyzed in real time using
an iCycler PCR machine and software (Biorad). Samples that
did not amplify were scored as negative, and all samples were
grouped into 3 categories based on these results: (+/+), positive
f o rb o t hE 6D N Aa n dE 6R N A ;( +/2), positive for E6 DNA,
but transcriptionally silent; and (2/2), negative for E6 DNA
and RNA. HPV status was successfully determined for 24 of the
26 HNSCC samples, and these were used for subsequent
analyses utilizing HPV status.
10K SNPChip LOH analysis
HNSCC genomic DNAs were extracted using the standard
TriZol-extraction protocol; they were further purified by
ethanol precipitation before and after whole genome amplifi-
cation using the GenomiPhi kit (GE Healthcare). The
Affymetrix 10K Xba131 array contains approximately 11,500
SNPs with an average spacing of 210 kb. Standard Affymetrix
protocols were followed for these assays. Briefly, about 250 ng
genomic DNA was digested with XbaI and then ligated to
adaptors. Next, one-primer amplification was carried on by
using the GeneAmp PCR System 9700 (Applied Biosystems).
After purification with Qiagen MinElute 96 UF, a total of
about 20 mg of PCR product was fragmented and labeled with
biotin. Hybridization was performed in the Affymetrix Gene-
Chip Hybridization Oven at 48uC for 16–18 hours. Arrays
were washed and stained with the Affymetrix GeneChip Fludics
Station 400 and were scanned with the Affymetrix GeneArray
2500 Scanner. Image processing was performed with GCOS
1.0 software and genotypes were generated with GTYPE 2.0 or
higher software.
Statistical analysis
In order to assess the association between levels of methylation
and levels of HPV load (a similar analysis was also used to assess
the association between levels of methylation and T-N-M stage),
we proceeded as follows. All sample methylation values were
converted to ranks. One missing value for the LINE1-1 assay, for
sample P2, was imputed using the P2 value from the LINE1-3
(correlation between the LINE1-1 and LINE1-3 assays is 0.98).
These ranks were then scaled (weighted) by HPV load, with
weights of 0, 1 and 2 for 2/2, +/2, and +/+, respectively. The
final association ‘‘score’’ was the sum of these weighted ranks. The
null distribution for this score was assessed by simulations in which
we repeatedly allocated samples to HPV groups at random. We
ran one million simulations, and defined our p-value as two times
the proportion of cases in which the simulation score was as large
or larger than the one we actually saw. Our simulated p-value was
0.011.
Supporting Information
Table S1 Clinical and molecular features of HNSCC samples.
Found at: doi:10.1371/journal.pone.0004941.s001 (0.12 MB
DOC)
Figure S1 Dynamic range of PMA LINE-1 and Alu Assays.
Mixing experiments were performed to determine PMA methyl-
ation levels measured with varying proportions of universally
methylated and unmethylated DNA. UM.C and U2M.C repre-
sent commercially available (Chemicon) universally methylated
and unmethylated DNAs, respectively. UM.L and U2M.L were
generated from the same DNA by in vitro modification in our
laboratory.
Found at: doi:10.1371/journal.pone.0004941.s002 (0.10 MB TIF)
Figure S2 Correlation analysis of SINE and LINE global
methylation assays. A variety of tumor and normal cell line DNAs
were assayed with all six of our LINE and SINE assays (three
LINE-1 assays and three Alu assays). A. LINE-1 assays were highly
correlated with each other. B. Alu assays were highly correlated
with each other. C. However, LINE-1 and Alu assays were only
moderately correlated. Two representative plots are shown for
each series of comparisons.
Found at: doi:10.1371/journal.pone.0004941.s003 (0.19 MB TIF)
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